These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 15709161)
1. Profiling tumor counterattack: do Fas ligand-containing microvesicles reduce anticancer immunity? Bohana-Kashtan O; Civin CI Clin Cancer Res; 2005 Feb; 11(3):968-70. PubMed ID: 15709161 [No Abstract] [Full Text] [Related]
2. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166 [TBL] [Abstract][Full Text] [Related]
3. Tumor immunity in oral cancer: a clinico-pathological study. Jansa P; Podstata J; Pastrnák A Acta Univ Palacki Olomuc Fac Med; 1987; 117():95-106. PubMed ID: 2977715 [No Abstract] [Full Text] [Related]
4. Fas signaling induces raft coalescence that is blocked by cholesterol depletion in human RPE cells undergoing apoptosis. Lincoln JE; Boling M; Parikh AN; Yeh Y; Gilchrist DG; Morse LS Invest Ophthalmol Vis Sci; 2006 May; 47(5):2172-8. PubMed ID: 16639029 [TBL] [Abstract][Full Text] [Related]
5. [The significance of immunologic parameters for preoperative prognostication in carcinoma of the mouth]. Hyckel P; Metzner G; Müller P; Haroske D; Quade R Dtsch Z Mund Kiefer Gesichtschir; 1985; 9(6):461-8. PubMed ID: 3869490 [No Abstract] [Full Text] [Related]
6. Expression of Fas and Fas-ligand and analysis of argyrophilic nucleolar organizer regions in squamous cell carcinoma: relationships with tumor stage and grade, and apoptosis. Guler N; Uckan S; Celik I; Oznurlu Y; Uckan D Int J Oral Maxillofac Surg; 2005 Dec; 34(8):900-6. PubMed ID: 15907374 [TBL] [Abstract][Full Text] [Related]
7. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Ryan AE; Shanahan F; O'Connell J; Houston AM Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003 [TBL] [Abstract][Full Text] [Related]
8. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Tamaki S; Sanefuzi N; Kawakami M; Aoki K; Imai Y; Yamanaka Y; Yamamoto K; Ishitani A; Hatake K; Kirita T Hum Immunol; 2008 Feb; 69(2):88-93. PubMed ID: 18361932 [TBL] [Abstract][Full Text] [Related]
9. Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression. Prado-Garcia H; Aguilar-Cazares D; Meneses-Flores M; Morales-Fuentes J; Lopez-Gonzalez JS Cancer Immunol Immunother; 2008 Mar; 57(3):325-36. PubMed ID: 17668204 [TBL] [Abstract][Full Text] [Related]
10. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege. Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of cell-mediated immunity in oral cancer patients. Rao RS; Fakih AR; Nair CN; Gangal SG; Naik SL Indian J Cancer; 1984 Nov-1985 Jan; 21(5-6):141-5. PubMed ID: 6336234 [No Abstract] [Full Text] [Related]
12. Glutathione, ascorbic acid and antioxidant enzymes in the tumor tissue and blood of patients with oral squamous cell carcinoma. Fiaschi AI; Cozzolino A; Ruggiero G; Giorgi G Eur Rev Med Pharmacol Sci; 2005; 9(6):361-7. PubMed ID: 16479741 [TBL] [Abstract][Full Text] [Related]
13. FasL gene therapy: a new therapeutic modality for head and neck cancer. ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918 [TBL] [Abstract][Full Text] [Related]
14. Membrane vesicles shed by oligodendroglioma cells induce neuronal apoptosis. D'Agostino S; Salamone M; Di Liegro I; Vittorelli ML Int J Oncol; 2006 Nov; 29(5):1075-85. PubMed ID: 17016637 [TBL] [Abstract][Full Text] [Related]
15. The role of the tumor necrosis factor (TNF)--Fas L and HCV in the development of hepatocellular carcinoma. Nada O; Abdel-Hamid M; Ismail A; El Shabrawy L; Sidhom KF; El Badawy NM; Ghazal FA; El Daly M; El Kafrawy S; Esmat G; Loffredo CA J Clin Virol; 2005 Oct; 34(2):140-6. PubMed ID: 16157266 [TBL] [Abstract][Full Text] [Related]
16. A high concentration of MMP-2/gelatinase A and MMP-9/gelatinase B reduce NK cell-mediated cytotoxicity against an oral squamous cell carcinoma cell line. Lee BK; Kim MJ; Jang HS; Lee HR; Ahn KM; Lee JH; Choung PH; Kim MJ In Vivo; 2008; 22(5):593-7. PubMed ID: 18853752 [TBL] [Abstract][Full Text] [Related]
19. Serum protein thiol in oral squamous cell carcinoma. Subash P; Das M; Rao A Clin Chim Acta; 2006 Jun; 368(1-2):199-200. PubMed ID: 16516879 [No Abstract] [Full Text] [Related]
20. The relationship between the expression of the epithelial blood-group substances and malignancy: a preliminary report. George DI; Hanks CT; Courtney RM; Lopatin DE J Dent Res; 1980 May; 59(5):831. PubMed ID: 6928873 [No Abstract] [Full Text] [Related] [Next] [New Search]